Stock PYC PYC THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Market Closed - Australian S.E.
Other stock markets
 02:10:46 2024-04-30 am EDT 		5-day change 1st Jan Change
0.097 AUD +5.43% Intraday chart for PYC Therapeutics Limited +7.78% -11.82%
Apr. 22 Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data MT
Apr. 22 PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data
MT
PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study
MT
PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced
MT
PYC Therapeutics Raises AU$40 Million via Entitlement Offer
MT
Rights Issue: 1 new share @ 0.08 AUD for 4 existing shares
FA
PYC Therapeutics to Raise Up to AU$75 Million for Advancing Drug Candidates
MT
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
PYC Therapeutics Receives AU$4.5 Million Upfront Fee for Drug Discovery Collaboration
MT
Transcript : PYC Therapeutics Limited - Special Call
PYC Therapeutics to Launch Google Cloud-Hosted Drug Discovery Project; Shares Fall 5%
MT
Transcript : PYC Therapeutics Limited - Shareholder/Analyst Call
Transcript : PYC Therapeutics Limited - Special Call
Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease
CI
PYC Therapeutics Completes Dosing in Second Patient Cohort for Retinitis Pigmentosa Clinical Trial
MT
PYC Reports Positive Results from Preclinical Studies of Rare Eye Disease Drug
MT
Transcript : PYC Therapeutics Limited - Special Call
PYC Therapeutics Advances to Second Dose Cohort of Phase 1 Trial Following Safety Clearance
MT
PYC Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program
CI
PYC Therapeutics Raises Vision Pharma Shareholding to 96.2%
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PYC Stock
  4. News PYC Therapeutics Limited